Residency · Residency · Medical Genetics Genomics
Huntington Disease: Predictive Testing and Management
Introduction
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene on chromosome 4p16.3. With a prevalence of approximately 5-10 per 100,000 in populations of European ancestry, HD is characterized by progressive motor dysfunction, cognitive decline, and psychiatric disturbance. HD serves as a paradigm for predictive genetic testing and raises critical ethical considerations in clinical genetics practice.
Molecular Genetics
The CAG Repeat
Normal alleles contain 10-26 CAG repeats. Intermediate alleles (27-35 repeats) are not associated with disease but may expand in future generations. The reduced penetrance range (36-39 repeats) shows variable expression, with some individuals remaining unaffected. Full penetrance occurs at 40 or more repeats, with virtually certain disease development if lifespan is sufficient. Juvenile HD typically involves more than 60 repeats and is often paternally inherited.
| CAG Repeat Range | Classification | Clinical Significance |
|---|---|---|
| 10–26 | Normal | No risk of HD; stable on transmission |
| 27–35 | Intermediate | No disease; may expand to penetrant range in offspring (especially paternal) |
| 36–39 | Reduced penetrance | Variable; some develop HD, others remain unaffected |
| 40+ | Full penetrance | HD will develop if lifespan is sufficient |
| 60+ | Juvenile HD | Early onset (<20 years); rigid-akinetic phenotype; often paternal transmission |
Anticipation
CAG repeat length tends to increase during paternal transmission due to spermatogenesis instability, explaining the phenomenon of earlier onset in successive generations. Maternal transmission is more stable but expansion can still occur.
Genotype-Phenotype Correlation
CAG repeat length accounts for approximately 50-70% of variance in age of onset. The remaining variance is attributed to genetic modifiers (including DNA mismatch repair genes such as MSH3, PMS1, and MLH1) and environmental factors. Repeat length does not predict rate of progression or specific symptoms.
Clinical Features
Motor Symptoms
Chorea (involuntary, irregular, flowing movements) is the hallmark of adult-onset HD. Dystonia (sustained abnormal postures) is more prominent in juvenile-onset disease. Progressive bradykinesia and rigidity dominate late-stage disease. Oculomotor dysfunction with impaired saccades is often an early sign. Dysarthria, dysphagia, and gait instability develop progressively.
Cognitive Decline
Executive dysfunction (impaired planning, judgment, and cognitive flexibility) characterizes the cognitive decline, which follows a progressive subcortical dementia pattern. Slowed processing speed and difficulty with multitasking are typical.
Psychiatric Manifestations
Depression is the most common psychiatric feature, affecting up to 50% of patients. Irritability, apathy, anxiety, and obsessive-compulsive behaviors are frequent. Suicidal ideation carries highest risk around the time of diagnosis and during the early symptomatic phase. Psychosis occurs in approximately 5-10% of patients.
Juvenile-Onset HD (Westphal Variant)
Onset before age 20 with typically more than 60 CAG repeats produces a rigid-akinetic presentation rather than choreiform. Seizures and rapid cognitive decline characterize a more aggressive course.
Neuropathology
Selective striatal degeneration primarily affects the caudate nucleus and putamen, with medium spiny neurons expressing DARPP-32 being most vulnerable. Progressive cortical atrophy follows in later stages. Vonsattel grading (0-4) is based on degree of striatal pathology.
Predictive and Diagnostic Testing
Diagnostic Testing
Diagnostic testing is indicated for symptomatic individuals with suspected HD. CAG repeat sizing by PCR-based fragment analysis is the standard method, with careful attention to repeat ranges and the reduced penetrance zone in result interpretation.
Predictive Testing Protocol
For asymptomatic at-risk individuals, predictive testing follows international guidelines (HDSA/IHA). A multidisciplinary team includes a geneticist, genetic counselor, neurologist, and psychologist/psychiatrist. A minimum of two pre-test counseling sessions with psychological assessment is required, followed by a mandatory waiting period (typically one month) between the decision and blood draw. In-person result disclosure with a support person present is standard, with post-test follow-up regardless of result.
Ethical Considerations
Nondirective counseling ensures that the decision to test remains autonomous. The right not to know must be respected, including from family pressure. Testing of minors is generally not recommended for adult-onset conditions. Exclusion testing in prenatal/preimplantation settings allows determination of fetal risk without revealing the parent's status. GINA provides limited protections that do not cover life, disability, or long-term care insurance.
Prenatal and Preimplantation Testing
Preimplantation genetic testing (PGT) is available for at-risk couples. Prenatal diagnosis via CVS or amniocentesis with CAG repeat analysis is an option. Exclusion testing using linkage analysis is possible when a parent does not wish to know their own status.
Management
Pharmacologic Treatment
Tetrabenazine and deutetrabenazine (VMAT2 inhibitors) are FDA-approved for chorea. Antipsychotics (olanzapine, risperidone) manage chorea, psychosis, and behavioral symptoms. SSRIs are first-line for depression and anxiety. Valproate and benzodiazepines serve as adjuncts for seizures in juvenile HD and myoclonus. No disease-modifying therapy is currently approved.
Multidisciplinary Care
Physical therapy addresses mobility and fall prevention. Speech and swallowing therapy manages dysphagia to prevent aspiration. Nutritional support addresses the high caloric needs from hyperkinetic movements. Cognitive rehabilitation and behavioral strategies assist with daily functioning. Psychiatric monitoring with active suicide risk assessment is ongoing. Palliative care is integrated as disease progresses.
Emerging Therapies
HTT-lowering strategies using antisense oligonucleotides (tominersen) showed promise but Phase 3 trials were halted due to adverse effects. Splicing modulators (branaplam and related compounds) are being explored. Somatic repeat expansion inhibitors targeting the mismatch repair pathway represent a novel approach. Gene therapy using AAV-delivered miRNA and zinc finger repressors is in preclinical development.
Clinical Pearls
HD predictive testing requires a structured, multistep protocol with psychological support -- it is not a routine genetic test. Approximately 5-25% of at-risk individuals elect to undergo predictive testing after counseling. The reduced penetrance zone (36-39 repeats) creates significant counseling challenges as disease may or may not manifest. Depression and suicidality are treatable and should be actively screened for throughout the disease course, particularly around the time of genetic testing and diagnosis.
References
- McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol. 2018;25(1):24-34.
- MacLeod R, Tibben A, et al. Recommendations for the predictive genetic test in Huntington's disease. Clin Genet. 2013;83(3):221-231.
- Genetic Modifiers of Huntington's Disease Consortium. CAG repeat not polyglutamine length determines timing of Huntington's disease onset. Cell. 2019;178(4):887-900.
- Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16(10):529-546.